RecruitingNCT06241521
Myasthenia Gravis Registry in China
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Huashan Hospital
- Enrollment
- 1500 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2035
Study locations (16)
- Beijing Hospital, Beijing, Beijing Municipality, China
- Xuanwu hospital, Capital medical university, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- The Third Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Xiangya hospital, Central south university, Changsha, Hunan, China
- The First Hospital, Soochow University, Suzhou, Jiangsu, China
- Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- The First Hospital, Jilin University, Changchun, Jilin, China
- Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- Tangdu Hospital, The Air Force Medical University, Xi’an, Shanxi, China
- West China Hospital, Sichuan University, Chengdu, Sichuan, China
- +1 more locations on ClinicalTrials.gov
Collaborators
China Alliance for Rare Diseases · National Center for Neurological Disorders (China) · China myasthenia gravis collaborating group (CMGCG)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06241521 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.